IGFBP Peptide Fragments for Neurodevelopmental Disorder Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodevelopmental disorders such as Phelan-McDermid Syndrome and autism spectrum disorders are limited, with no disease-modifying therapies available, and existing interventions are costly and have varying degrees of success due to the disorder's immense etiological heterogeneity.
Innovation Solution
Development of insulin-like growth factor binding protein (IGFBP) peptide fragments, specifically peptides with sequences like KHGLYNLKQCKMSLNGQ and PKKLRP, which are cyclized and modified with N-terminal carboxylation and C-terminal amidation, for administration to treat depression, PTSD, and various central nervous system and neurodevelopmental disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for neurodevelopmental disorders, then symptom management is achieved, but no disease-modifying therapy is available and costs are high
Solution Approach 1:
The patent extracts specific functional peptide fragments from the larger IGFBP protein sequence. By isolating and utilizing only the essential peptide sequences (such as KHGLYNLKQCKMSLNGQ and PKKLRP) responsible for binding insulin-like growth factor, the invention creates simplified therapeutic agents that achieve disease-modifying effects without the complexity of full protein therapy or conventional pharmacological treatments.
Solution Approach 2:
The patent modifies the peptide sequences through various parameters including cyclization, N-terminal carboxylation, C-terminal amidation, and halogen substitution. These parameter changes enhance the peptide stability, binding affinity, and therapeutic efficacy while maintaining a simplified molecular structure compared to conventional drugs.
2Adaptability or versatility
If existing interventions are used, then treatment is provided, but costs are high and success varies due to etiological heterogeneity
Solution Approach 1:
The IGFBP peptide fragments demonstrated in the patent exhibit broad therapeutic potential across multiple neurodevelopmental disorders including autism spectrum disorders, Phelan-McDermid Syndrome, and other conditions. The peptides serve multiple functions: binding insulin-like growth factor, modulating neural development, and providing therapeutic effects without the need for disorder-specific treatments, thereby reducing overall treatment costs and improving accessibility.
3Reliability
If full-length IGFBP protein is used, then therapeutic effect is achieved, but peptide stability and bioavailability are improved through fragmentation and modification
Solution Approach 1:
The patent segments the full-length IGFBP protein into functional peptide fragments (such as the 18-40 amino acid sequences KHGLYNLKQCKMSLNGQ and PKKLRP). This segmentation improves stability and bioavailability by creating smaller, more resistant-to-degradation molecules while maintaining the essential binding function for insulin-like growth factor, thus achieving therapeutic effects with enhanced pharmacological properties.
Data Source
AI summary
Described herein are isolated peptides, compositions comprising the same, and methods of using such peptides or compositions in the treatment of depression, central nervous system disorders, and neurodevelopmental disorders.